PHASE II CLINICAL TRIAL WITH AN AMPA-POSITIVE ALLOSTERIC MODULATOR (S 47445): BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS SUFFERING FROM ALZHEIMER’S DISEASE AT MILD TO MODERATE STAGES WITH DEPRESSIVE SYMPTOMS